Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 5, 2008
app pub date -
Dec 4, 2006
filing date -
Dec 4, 2006
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor that results in significant modulation of the infiltrating immune cells shown by a decrease in CD8+ T cells and a significant increase in tumor infiltrating CD4+ T cells. A dose of 800 IU/day as IL-2 for 5 days per week for 3 weeks of a Leukocyte Interleukin Injection (LI) being a serum-free and mitogen-free mixture comprised of specific ratios of cytokines IL-1.beta., TNF-.alpha., IFN-.gamma. and GM-CSF to Interleukin 2 (IL-2) resulted in a paradigm shift. The paradigm shift is defined as a marked CD4+ T cell infiltrate and a clear and specific change in the density and localization of antigen presenting cells such as dendritic cells and inflammatory cells, particularly neutrophils in cancer nests.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully